{ "id": "epfqggatfq", "slug": "opioid-receptor-epfqggatfq", "title": "Μ-opioid receptor", "updated": "2026-10-21", "topic_path": [ { "id": "life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/topics/life" }, { "id": "life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health" }, { "id": "life.health.medicines", "label": "Medicines and therapeutics", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines" }, { "id": "life.health.medicines.cns-psychiatric-medications", "label": "Psychiatric and neurological medications", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines.cns-psychiatric-medications" } ], "geo": [ { "id": "geo.us.t1946.life.health.medicines.cns-psychiatric-medications", "label": "United States · 1946 to 2000: Psychiatric and neurological medications", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.us.t1946.life.health.medicines.cns-psychiatric-medications", "path": [ { "id": "geo.us", "label": "United States", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.us" }, { "id": "geo.us.t1946", "label": "United States · 1946 to 2000", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.us.t1946" }, { "id": "geo.us.t1946.life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.us.t1946.life" }, { "id": "geo.us.t1946.life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.us.t1946.life.health" }, { "id": "geo.us.t1946.life.health.medicines", "label": "Medicines and therapeutics", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.us.t1946.life.health.medicines" }, { "id": "geo.us.t1946.life.health.medicines.cns-psychiatric-medications", "label": "Psychiatric and neurological medications", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.us.t1946.life.health.medicines.cns-psychiatric-medications" } ] } ], "excerpt": "Μ-opioid receptor (MOR, OPRM1): principal 7-TM GPCR for endogenous opioid peptides and analgesic drugs; Gi/o signaling, β-arrestin desensitization; target of morphine, fentanyl, methadone, buprenorphine, naloxone.", "snippet": "Μ-opioid receptor (MOR, OPRM1): principal 7-TM GPCR for endogenous opioid peptides and analgesic drugs; Gi/o signaling, β-arrestin desensitization; target of morphine, fentanyl, methadone, buprenorphine, naloxone.", "node": "life.health.medicines.cns-psychiatric-medications", "markdown": "# Μ-opioid receptor\n\nThe μ-opioid receptor (MOR) is a seven-transmembrane G-protein-coupled receptor encoded by the human OPRM1 gene (HGNC:8156) and is the principal target of endogenous opioid peptides such as β-endorphin and the enkephalins, as well as of clinically used opioid analgesics.[1](https://ncbi.nlm.nih.gov/gene/4988) It is the main opioid receptor targeted in pain management and signals primarily by activating the inhibitory Gi pathway.[2](https://www.pnas.org/doi/10.1073/pnas.2013364117) MOR activation can produce analgesia, respiratory depression, and constipation; repeated or prolonged opioid exposure can lead to tolerance and physical dependence.[3](https://ncbi.nlm.nih.gov/books/NBK551554/)\n\n| Key fact | Detail |\n|---|---|\n| Gene and protein | OPRM1 (6q24-q25) encodes the canonical 7-transmembrane GPCR; some isoforms have only 6 transmembrane domains[1](https://ncbi.nlm.nih.gov/gene/4988) • [3](https://ncbi.nlm.nih.gov/books/NBK551554/) |\n| Signaling | Couples to Gi/o: lowers cAMP, closes calcium channels, opens GIRK channels, inhibits SNARE complexes; GRK phosphorylation recruits β-arrestins for desensitization and internalization[4](https://www.cell.com/cell/fulltext/S0092-8674(23)01180-7) • [5](https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1597922/full) |\n| Ligand affinities | Carfentanil Ki 2.4×10⁻¹¹ M, sufentanil Ki 1.38×10⁻¹⁰ M, fentanyl pKi 9.2, morphine pKi 9.0, methadone pKi 9.2, buprenorphine pKi 8.8, tramadol Ki 1.6×10⁻⁶ M[6](https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?familyId=50&familyType=GPCR&objectId=319) |\n| Endogenous ligands | [Met]enkephalin pKi 9.2, β-endorphin pKi 9.0, endomorphin-1 pKi 8.3, endomorphin-2 pKi 8.5, dynorphin peptides[6](https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?familyId=50&familyType=GPCR&objectId=319) |\n| Naloxone | Confirmed partial agonist activity of 10% to 30% across BRET assay systems, despite its clinical role as an antagonist[7](https://www.nature.com/articles/s41586-025-09677-6) |\n| Knockout phenotype | Exon-1 MOR knockout mice lose all systemic morphine and methadone analgesia[8](https://ncbi.nlm.nih.gov/pmc/articles/PMC2810866/) |\n| OUD medications | Methadone (full agonist), buprenorphine (partial agonist), and naltrexone (antagonist) all act at MOR[9](https://pmc.ncbi.nlm.nih.gov/articles/PMC6934219/) |\n\n## Structure and signaling mechanism\n\nThe canonical MOR belongs to the superfamily of seven-transmembrane-spanning G-protein-coupled receptors, with an extracellular [N-terminus](https://www.edgepedia.org/n-terminus); MOR-1 itself contains four exons that combine to form a wide range of splice variants, and some OPRM1 isoforms have only six transmembrane domains.[1](https://ncbi.nlm.nih.gov/gene/4988) • [8](https://ncbi.nlm.nih.gov/pmc/articles/PMC2810866/)\n\nOpioid receptors signal primarily through intracellular G proteins and GPCR kinases. Receptor activation couples to G-protein heterotrimers of Gα, Gβ, and Gγ subunits; the inhibitory Gαi/o lowers cellular cyclic AMP, closes calcium channels, opens GIRK potassium channels, and inhibits SNARE complexes, and the Gβγ subunits act on additional downstream pathways.[4](https://www.cell.com/cell/fulltext/S0092-8674(23)01180-7) • [5](https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1597922/full) The β-arrestin pathway, engaged after GRK phosphorylation, regulates signaling through receptor desensitization and internalization.[5](https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1597922/full) [Interaction](https://www.edgepedia.org/interaction) of β-arrestin-1 with the receptor core binding site appears less specific and occurs with much lower affinity than binding of Gi.[10](https://www.nature.com/articles/s41586-024-07295-2)\n\n**Structural snapshots.** Cryo-EM structures of the human MOR–Gi protein complex bound to morphine and to fentanyl, reported in 2022, defined the binding poses of two of the most used opioid drugs; both drugs confer analgesia and side effects through both G-protein and arrestin signaling pathways.[11](https://www.cell.com/cell/fulltext/S0092-8674%2822%2901260-0) In 2024, DEER and smFRET measurements showed that nine representative ligands, including naloxone, TRV130, PZM21, buprenorphine, morphine, DAMGO, and lofentanil, each fine-tune the conformational ensemble of the receptor, producing distinctive efficacies and signal bias; with low-efficacy G-protein-biased agonists the TM4–TM6 distance remained mostly in inactive conformations.[10](https://www.nature.com/articles/s41586-024-07295-2)\n\n## Ligands\n\n**Endogenous peptides.** [Met]enkephalin is a full agonist at MOR with pKi 9.2, β-endorphin binds with pKi 9.0, and the endomorphins bind with pKi 8.3 and 8.5; dynorphin peptides also bind.[6](https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?familyId=50&familyType=GPCR&objectId=319) Endomorphin displays high specificity toward MOR, whereas dynorphins, although activating all opioid receptors except NOPR, have a 100-fold higher potency toward KOR.[4](https://www.cell.com/cell/fulltext/S0092-8674(23)01180-7)\n\n**Exogenous agonists** span weak opioids such as codeine and tramadol and strong opioids including oxycodone, morphine, hydromorphone, meperidine, tapentadol, methadone, fentanyl, [sufentanil](https://www.edgepedia.org/sufentanil), and remifentanil.[3](https://ncbi.nlm.nih.gov/books/NBK551554/) IUPHAR-listed potencies include etonitazene EC50 3×10⁻¹¹ M and isotonitazene EC50 5×10⁻¹¹ M in cAMP assays, and mitragynine EC50 5×10⁻¹⁰ M in HEK293T cells expressing human MOR.[6](https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?familyId=50&familyType=GPCR&objectId=319) PZM21 is listed as a biased agonist with pKi 9.0 and pEC50 8.3 in a Gi/o activation assay.[6](https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?familyId=50&familyType=GPCR&objectId=319)\n\n**Antagonists.** Naloxone is one of the most common MOR antagonists and is used in overdose.[3](https://ncbi.nlm.nih.gov/books/NBK551554/) Structural work in 2025 nevertheless confirmed partial agonist activity of 10% to 30% for naloxone across BRET assay systems, and showed that naloxone stalls MOR in a \"latent\" state while loperamide promotes an \"engaged\" state poised for GDP release.[7](https://www.nature.com/articles/s41586-025-09677-6)\n\n## Physiology and distribution\n\nMORs are the most commonly expressed opioid receptors in the central nervous system, localized in the dorsal horn of the spinal cord (laminae I and II) and in the somatosensory cortex. Activation of presynaptic MORs inhibits release of the excitatory neurotransmitters substance P and glutamate, whereas activation of postsynaptic MORs directly hyperpolarizes postsynaptic neurons.[3](https://ncbi.nlm.nih.gov/books/NBK551554/)\n\nReceptors are also expressed in the gastrointestinal tract, where activation slows motility and produces constipation; in the pupil, producing miosis; and in immune cells including CD4+ T lymphocytes, monocytes/macrophages, and neutrophils.[3](https://ncbi.nlm.nih.gov/books/NBK551554/) Acute MOR activation effects include respiratory depression, slowed gastrointestinal motility, nausea, vomiting, constipation, dizziness, pruritus, cough suppression, miosis, hallucinations, dysphoria, and sedation; chronic use leads to tolerance, hyperalgesia, and physical dependence.[3](https://ncbi.nlm.nih.gov/books/NBK551554/)\n\n## By the numbers\n\nQuantitative anchors for receptor activation come from nucleotide-binding assays on the [G protein](https://www.edgepedia.org/g-protein). MOR in the apo state showed a GDPβS EC50 of 57 ± 14 nM; with loperamide this rose roughly 30-fold to 1.7 ± 0.7 µM, while naloxone gave 89 ± 8.5 nM and DAMGO 0.7 ± 0.16 µM. Agonist efficacy at MOR correlates with decreased GDP affinity promoting GTP exchange, whereas antagonists increase GDP affinity.[7](https://www.nature.com/articles/s41586-025-09677-6) The 2024 dynamics study placed ligands on an efficacy scale running from low-efficacy biased agonists (TRV130, PZM21, and buprenorphine) through morphine and the reference agonist DAMGO to the super-efficacy agonists BU72 and lofentanil.[10](https://www.nature.com/articles/s41586-024-07295-2)\n\n**Knockout evidence.** In exon-1 knockout mice lacking full-length MOR-1 variants, morphine actions were totally lost, as were those of methadone when given systemically, showing that MOR is necessary for these systemic morphine and methadone analgesic effects.[8](https://ncbi.nlm.nih.gov/pmc/articles/PMC2810866/) Morphine-6-glucuronide and 6-acetylmorphine, the active metabolite of heroin, retained analgesic activity in these mice, and this residual analgesia persisted in triple knockout mice also lacking δ and κ receptors as well as exon-1 of MOR-1.[8](https://ncbi.nlm.nih.gov/pmc/articles/PMC2810866/)\n\n## Analgesia versus tolerance and respiratory depression: the biased agonism debate\n\nThe classic hypothesis rested on β-arrestin2 knockout mice: short-term morphine-induced respiratory suppression and constipation are attenuated in βarr2-KO mice, naloxone-precipitated withdrawal after long-term morphine is attenuated, and β-arrestin2 deletion enhances morphine-induced antinociception and disrupts antinociceptive tolerance.[12](https://pmc.ncbi.nlm.nih.gov/articles/PMC3186080/) Some opioid ligands preferentially favor Gi signaling over β-arrestin recruitment, and the β-arrestin pathway was proposed to induce adverse effects such as respiratory depression.[2](https://www.pnas.org/doi/10.1073/pnas.2013364117)\n\n**Clinical test.** [Oliceridine](https://www.edgepedia.org/oliceridine) (TRV130), a G-protein-biased MOR agonist with reduced β-arrestin signaling, was approved by the FDA in 2020 and showed decreased risk of constipation and respiratory depression; however, it has abuse liability similar to other opioid analgesics in both human and animal studies.[5](https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1597922/full) Fentanyl, methadone, and oxycodone show no differences among genotypes in their ability to induce physical dependence in β-arrestin2 knockout mice, exemplifying agonist-mediated differences in β-arrestin2 function.[12](https://pmc.ncbi.nlm.nih.gov/articles/PMC3186080/)\n\n**Reassessment.** A 2024 study proposed that overly strong G-protein signaling (super-efficacy) contributes to respiratory depression and that partial agonists with lower efficacy may provide a safer therapeutic profile, challenging the earlier β-arrestin hypothesis of respiratory depression.[10](https://www.nature.com/articles/s41586-024-07295-2) The two positions differ on mechanism: the older view attributes respiratory depression to the β-arrestin pathway,[2](https://www.pnas.org/doi/10.1073/pnas.2013364117) the newer one to G-protein super-efficacy.[10](https://www.nature.com/articles/s41586-024-07295-2)\n\n## How it compares with other opioid receptors\n\nThe human opioid receptor family comprises MOR, DOR (δ), KOR (κ), and the NOP receptor. MOR has high affinity and modest selectivity for enkephalin-derived peptides; DOR has high affinity for all but dynorphin-derived peptides; KOR preferentially binds dynorphin-derived peptides and the natural product salvinorin A; and NOPR interacts specifically with nociceptin-derived peptides.[4](https://www.cell.com/cell/fulltext/S0092-8674(23)01180-7) The NOP receptor is classified as \"opioid-related\" rather than opioid because it exhibits a distinct pharmacology.[13](https://doi.org/10.2218/gtopdb/f50/2025.3) The Greek letter nomenclature μ, δ, and κ is well established and retained in the current IUPHAR/BPS Guide to [Pharmacology](https://www.edgepedia.org/pharmacology) (v2025.3), along with the symbols spelled out as mu, delta, and kappa.[13](https://doi.org/10.2218/gtopdb/f50/2025.3)\n\n## Genetic variation and pharmacogenomics\n\nAll MOR splice variants designated MOR-1A through MOR-1X are transcribed from the single OPRM1 gene at chromosomal location 6q24-q25; the Ser268→Pro variant receptor significantly reduces coupling efficiency and is less desensitized upon agonist exposure.[3](https://ncbi.nlm.nih.gov/books/NBK551554/)\n\nThe best-studied variant is the single nucleotide polymorphism Asn40→Asp (A118G). NCBI Gene records that the NM_001008503.2:c.118A>G allele has been associated with opioid and alcohol addiction and variations in pain sensitivity, but that evidence for a causal role is conflicting.[1](https://ncbi.nlm.nih.gov/gene/4988) Clinical references report associations with increased risk of opioid addiction and altered dose requirements.[3](https://ncbi.nlm.nih.gov/books/NBK551554/) Beyond opioids, MOR has an important role in dependence to other drugs of abuse, such as nicotine, cocaine, and alcohol, via its modulation of the dopamine system.[1](https://ncbi.nlm.nih.gov/gene/4988)\n\n## Opioid use disorder pharmacology\n\nThree FDA-approved medications for opioid use disorder target MOR: methadone, a full MOR agonist; buprenorphine, a partial MOR agonist that is also a KOR antagonist and nociceptor receptor agonist; and naltrexone, a MOR and KOR antagonist.[9](https://pmc.ncbi.nlm.nih.gov/articles/PMC6934219/) [Buprenorphine](https://www.edgepedia.org/buprenorphine) induces typical opioid effects up to a ceiling, limiting euphoria and respiratory depression, and its very high receptor affinity prevents displacement by full agonists such as heroin; methadone's long half-life allows treatment without destructive behaviors.[3](https://ncbi.nlm.nih.gov/books/NBK551554/)\n\nThese medications are associated with reduced risk of relapse, overdose deaths, infections, and criminal behavior, and are more cost-effective than no OUD treatment or treatment with no medication; MOR is simultaneously the therapeutic target of these drugs and the target through which heroin and other misused opioids produce rewarding effects.[9](https://pmc.ncbi.nlm.nih.gov/articles/PMC6934219/) For the antagonist option, immediate-release naltrexone's utility is limited by poor adherence; the monthly extended-release formulation (XR-NTX) improved treatment retention, and current recommendations call for one week of abstinence before induction because naltrexone triggers acute withdrawal in non-detoxified patients.[9](https://pmc.ncbi.nlm.nih.gov/articles/PMC6934219/)\n\n## What has changed since 2023\n\nThree developments stand out. First, structural biology has moved from single active-state structures to conformational ensembles: the 2024 DEER/smFRET study showed ligand-specific tuning of the TM6 activation pathway across nine ligands,[10](https://www.nature.com/articles/s41586-024-07295-2) and the 2025 nucleotide-release study delivered 8 structural models and 16 cryo-EM maps of MOR with naloxone or loperamide capturing intermediate conformations along the activation pathway.[7](https://www.nature.com/articles/s41586-025-09677-6) Second, a 2024 study proposed that G-protein super-efficacy contributes to respiratory depression, challenging the β-arrestin hypothesis; it also proposed low-efficacy partial agonists as a potentially safer design direction.[10](https://www.nature.com/articles/s41586-024-07295-2) Third, nomenclature has been continuous: the 2025.3 IUPHAR/BPS database retains the established μ, δ, and κ designations unchanged.[13](https://doi.org/10.2218/gtopdb/f50/2025.3)\n\n## References\n\n1. [OPRM1 opioid receptor mu 1 [Homo sapiens] – NCBI Gene](https://ncbi.nlm.nih.gov/gene/4988)\n2. [Exploring the activation pathway and Gi-coupling specificity of the μ-opioid receptor, PNAS](https://www.pnas.org/doi/10.1073/pnas.2013364117)\n3. [Mu Receptors, StatPearls/NCBI Bookshelf](https://ncbi.nlm.nih.gov/books/NBK551554/)\n4. [Molecular basis of opioid receptor signaling, Cell (2023)](https://www.cell.com/cell/fulltext/S0092-8674(23)01180-7)\n5. [Molecular and cellular basis of mu-opioid receptor signaling, Frontiers in Neuroscience (2025)](https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1597922/full)\n6. [μ receptor, IUPHAR Guide to Pharmacology](https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?familyId=50&familyType=GPCR&objectId=319)\n7. [Structural snapshots capture nucleotide release at the μ-opioid receptor, Nature (2025)](https://www.nature.com/articles/s41586-025-09677-6)\n8. [Molecular Insights Into μ Opioid Pharmacology: From the Clinic to the Bench](https://ncbi.nlm.nih.gov/pmc/articles/PMC2810866/)\n9. [Medications for opioid use disorders: clinical and pharmacological considerations](https://pmc.ncbi.nlm.nih.gov/articles/PMC6934219/)\n10. [Ligand efficacy modulates conformational dynamics of the µ-opioid receptor, Nature (2024)](https://www.nature.com/articles/s41586-024-07295-2)\n11. [Molecular recognition of morphine and fentanyl by the human μ-opioid receptor, Cell (2022)](https://www.cell.com/cell/fulltext/S0092-8674%2822%2901260-0)\n12. [Functional Selectivity at the μ-Opioid Receptor](https://pmc.ncbi.nlm.nih.gov/articles/PMC3186080/)\n13. [Opioid receptors in GtoPdb v.2025.3](https://doi.org/10.2218/gtopdb/f50/2025.3)\n\n---\n*Topic: Encyclopedia › Life and health › Human health and medicine › Medicines and therapeutics › Psychiatric and neurological medications*\n\n*Initially written Sep 17, 2026 · Reviewed: Sep 30, 2026; Oct 21, 2026 · Edited: Sep 30, 2026; Oct 15, 2026; Oct 21, 2026 · Last review: Oct 21, 2026*\n\n*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*\n\nLicense: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license\n", "same_as": [], "url": "https://www.edgepedia.org/opioid-receptor-epfqggatfq", "markdown_url": "https://www.edgepedia.org/opioid-receptor-epfqggatfq.md", "license": { "name": "Edgepedia Community License 1.0", "url": "https://www.edgepedia.org/edgepedia/license", "summary": "Free with credit, commercial use included. AI training is open to everyone. For other uses, organizations over USD 100M in revenue or 100M monthly users license separately.", "spdx": "LicenseRef-Edgepedia-Community-1.0" }, "credit": "\"Μ-opioid receptor\", Edgepedia (EdgeChat), https://www.edgepedia.org/opioid-receptor-epfqggatfq. Edgepedia Community License 1.0.", "credit_md": "\"[Μ-opioid receptor](https://www.edgepedia.org/opioid-receptor-epfqggatfq)\", Edgepedia (EdgeChat), [https://www.edgepedia.org/opioid-receptor-epfqggatfq](https://www.edgepedia.org/opioid-receptor-epfqggatfq). [Edgepedia Community License 1.0](https://www.edgepedia.org/edgepedia/license).", "credit_html": "\"Μ-opioid receptor\", Edgepedia (EdgeChat), https://www.edgepedia.org/opioid-receptor-epfqggatfq. Edgepedia Community License 1.0.", "speakable": "Μ-opioid receptor: principal 7-TM GPCR for endogenous opioid peptides and analgesic drugs; Gi/o signaling, β-arrestin desensitization; target of morphine, fentanyl, methadone, buprenorphine, naloxone." }